Download FREE Report Sample
Download Free sampleThe global Rivaroxaban market was valued at 7407.64 Million USD in 2021 and will grow with a CAGR of 9.04% from 2021 to 2027, based on Research newly published report.
The prime objective of Rivaroxaban Market is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, Rivaroxaban Market covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8-12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.The global average price of Rivaroxaban is in the decreasing trend, from 5.62 USD/Unit in 2011 to 5.34 USD/Unit in 2015. With the situation of global economy, prices will be in slowly decreasing trend in the following five years.
By Market Verdors:
By Types:
By Applications:
Key Indicators Analysed
Key Reasons to Purchase
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy